# PRESS RELEASE

## Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

**Houston, Texas and Tuebingen, Germany, October 4, 2024** – Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024.

Full abstracts will be available on November 5, 2024, at 9:00 am EST in the *JITC* Supplement.

**Oral Presentations**

**Date / Time:** November 8, 2024 / 3:50 – 5:25 pm Central Standard Time
**Session:** Oral Abstract Session 1
**Abstract Number**: 687
**Title:** ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients
**Presenter:** Martin Wermke, M.D. (University Hospital Dresden, Germany)

**Date / Time:** November 9, 2024 / 12:30 PM - 1:30 pm Central Standard Time
**Session:** Rapid Oral - Clinical 2
**Abstract Number**: 661
**Title:** Enhanced pharmacology data of next-generation IMA203CD8 TCR-T monotherapy targeting PRAME
**Presenter:** Dejka M. Araujo, M.D. (MD Anderson Cancer Center, Houston, Texas, USA)

**Poster Presentations**

**Date:** November 8, 2024
**Poster Number**: 355
**Title:** An approach to bridging starting materials to monitor T cell persistence in adoptive T cell therapy
**Presenter:** Jourdan Andersson, Ph.D. (Immatics)

**Date:** November 9, 2024
**Poster Number**: 226

**Title:** An effective donor screening program for manufacturing of allogeneic γδ T cell products
**Presenter:** Inbar Azoulay Alfaguter, Ph.D. (Immatics)

**Date:** November 9, 2024
**Poster Number**: 228
**Title:** Optimizing and streamlining the manufacturing of Vγ9Vδ2 γδ T cells for allogeneic therapy
**Presenter:** Pooja Mehta, Ph.D. (Immatics)

**Date:** November 9, 2024
**Abstract Number**: 360
**Title:** Combination of a TCR-engineered autologous PRAME-targeting T cell therapy with a PRAME-encoding mRNA for the treatment of solid tumors
**Presenter:** Fabian Brunk, Ph.D. (Immatics)

**Date:** November 9, 2024
**Poster Number**: 372
**Title:** TCR-engineered T cells exhibit enhanced persistence and serial killing ability when armored with membrane-bound IL-15
**Presenter:** Justin Gunesch, Ph.D. (Immatics)

**About IMA203 and Target PRAME**
ACTengine® IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME), a protein frequently expressed in a large variety of solid cancers, thereby supporting the program's potential to address a broad cancer patient population. Immatics' PRAME peptide is present at a high copy number per tumor cell and is homogeneously and specifically expressed in tumor tissue. The peptide has been identified and characterized by Immatics' proprietary mass spectrometry-based target discovery platform, XPRESIDENT®. Through its proprietary TCR discovery and engineering platform XCEPTOR®, Immatics has generated a highly specific T cell receptor (TCR) against this target for its TCR-based cell therapy approach, ACTengine® IMA203.

ACTengine® IMA203 TCR-T is currently being evaluated in Phase 1 IMA203 monotherapy, and IMA203CD8 (GEN2) monotherapy, where IMA203 engineered T cells are co-transduced with a CD8αβ co-receptor.

**About Immatics**
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of

Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on X, Instagram and LinkedIn.

**For more information, please contact:**

**Media**
Trophic Communications
Phone: +49 171 3512733
immatics@trophic.eu

**Immatics N.V.**
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325
InvestorRelations@immatics.com